Shiyang Kang

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Nan Chen, Wenfeng Fang, Jianhua Zhan et al. · Journal of Thoracic Oncology · 2015 · 686 citations · Full text

Medicine, Immunology, Oncology +17

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

Wenfeng Fang, Jianwei Zhang, Shaodong Hong et al. · Oncotarget · 2014 · 390 citations · Full text

Life Sciences, Cancer Biology, Oncology +16

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

Yanna Tang, Wenfeng Fang, Yaxiong Zhang et al. · Oncotarget · 2015 · 243 citations · Full text

Medicine, Oncology, Molecular Oncology +14

Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

Shaodong Hong, Nan Chen, Wenfeng Fang et al. · OncoImmunology · 2015 · 134 citations · Full text

Life Sciences, Immunology, Oncology +17

JTC-801 alleviates mechanical allodynia in paclitaxel-induced neuropathic pain through the PI3K/Akt pathway

Jingxiu Huang, Dongtai Chen, Yan Fang et al. · European Journal of Pharmacology · 2020 · 48 citations

Life Sciences, Molecular Medicine, Pharmacology +14